# Study to Determine the Effect of a High-Fat Meal on the Relative Bioavailability and Pharmacokinetics of a Single Dose of Bosutinib Administered Orally to Healthy Subjects

> **NCT00721474** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 24 (estimated)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Bosutinib
- **DRUG:** Bosutinib

## Key facts

- **NCT ID:** NCT00721474
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2009-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00721474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00721474, "Study to Determine the Effect of a High-Fat Meal on the Relative Bioavailability and Pharmacokinetics of a Single Dose of Bosutinib Administered Orally to Healthy Subjects". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00721474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*